JP2017515840A5 - - Google Patents

Download PDF

Info

Publication number: JP2017515840A5
Authority: JP; Japan
Prior art keywords: pharmaceutical composition; combination; pharmaceutically acceptable; composition according; compound
Prior art date: 2015-05-08
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP2016567399A

Other languages

English (en)

Japanese (ja)

Other versions

JP2017515840A (ja

Filing date

2015-05-08

Publication date

2018-05-31

2015-05-08 Application filed filed Critical

2015-05-08 Priority claimed from PCT/IB2015/053373 external-priority patent/WO2015173701A2/en

2017-06-15 Publication of JP2017515840A publication Critical patent/JP2017515840A/ja

2018-05-31 Publication of JP2017515840A5 publication Critical patent/JP2017515840A5/ja

Status Pending legal-status Critical Current

Links

150000001875 compounds Chemical class 0.000 claims 16
239000008194 pharmaceutical composition Substances 0.000 claims 14
229940123424 Neuraminidase inhibitor Drugs 0.000 claims 9
239000002911 sialidase inhibitor Substances 0.000 claims 9
150000003839 salts Chemical class 0.000 claims 7
NGYNBSHYFOFVLS-LBPRGKRZSA-N 1-[4-chloro-2-hydroxy-3-[(3s)-piperidin-3-yl]sulfonylphenyl]-3-(3-fluoro-2-methylphenyl)urea Chemical compound CC1=C(F)C=CC=C1NC(=O)NC1=CC=C(Cl)C(S(=O)(=O)[C@@H]2CNCCC2)=C1O NGYNBSHYFOFVLS-LBPRGKRZSA-N 0.000 claims 6
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims 6
VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 claims 6
229960003752 oseltamivir Drugs 0.000 claims 6
229960001028 zanamivir Drugs 0.000 claims 6
ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 claims 6
239000003814 drug Substances 0.000 claims 5
238000004519 manufacturing process Methods 0.000 claims 5
208000035473 Communicable disease Diseases 0.000 claims 4
206010057190 Respiratory tract infections Diseases 0.000 claims 4
208000015181 infectious disease Diseases 0.000 claims 4
239000000546 pharmaceutical excipient Substances 0.000 claims 4
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 3
ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims 3
229950008454 favipiravir Drugs 0.000 claims 3
229960000329 ribavirin Drugs 0.000 claims 3
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 3
239000002253 acid Substances 0.000 claims 2
239000007864 aqueous solution Substances 0.000 claims 2
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims 2
229960004853 betadex Drugs 0.000 claims 2
229910000042 hydrogen bromide Inorganic materials 0.000 claims 2
206010022000 influenza Diseases 0.000 claims 2
238000001990 intravenous administration Methods 0.000 claims 2
NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 claims 1
229920000858 Cyclodextrin Polymers 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1

JP2016567399A 2014-05-12 2015-05-08 感染症を治療するためのダニリキシンを含む医薬組成物 Pending JP2017515840A (ja)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201461991754P	2014-05-12	2014-05-12
US61/991,754		2014-05-12
US201562149893P	2015-04-20	2015-04-20
US62/149,893		2015-04-20
US201562151013P	2015-04-22	2015-04-22
US62/151,013		2015-04-22
PCT/IB2015/053373 WO2015173701A2 (en)	2014-05-12	2015-05-08	Pharmaceutical compositions for treating infectious diseases

Publications (2)

Publication Number	Publication Date
JP2017515840A JP2017515840A (ja)	2017-06-15
JP2017515840A5 true JP2017515840A5 (2)	2018-05-31

Family

ID=53175574

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2016567399A Pending JP2017515840A (ja)	2014-05-12	2015-05-08	感染症を治療するためのダニリキシンを含む医薬組成物

Country Status (20)

Country	Link
US (2)	US20170100385A1 (2)
EP (1)	EP3142694A2 (2)
JP (1)	JP2017515840A (2)
KR (1)	KR20170003673A (2)
CN (1)	CN107072976A (2)
AU (2)	AU2015260841A1 (2)
CA (1)	CA2948441A1 (2)
CL (1)	CL2016002879A1 (2)
CR (1)	CR20160529A (2)
DO (1)	DOP2016000297A (2)
EA (1)	EA201692111A1 (2)
IL (1)	IL248779A0 (2)
MX (1)	MX2016014859A (2)
PE (1)	PE20170185A1 (2)
PH (1)	PH12016502243A1 (2)
SG (1)	SG11201609276RA (2)
TW (1)	TW201625247A (2)
UY (1)	UY36117A (2)
WO (1)	WO2015173701A2 (2)
ZA (1)	ZA201607729B (2)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112018011138A2 (pt) *	2015-11-30	2018-11-21	Glaxosmithkline Intellectual Property (No.	formulações para administração intravenosa
US20190054060A1 (en) *	2016-03-01	2019-02-21	Emerging Viral Therapeutics (HK) Limited	Compositions and methods for treatment of influenza virus
CN111265528A (zh)	2020-01-21	2020-06-12	中国人民解放军军事科学院军事医学研究院	法匹拉韦在治疗冠状病毒感染方面的应用
CN120346194A (zh) *	2020-04-01	2025-07-22	硫创治疗公司	用于治疗乙型冠状病毒感染的半胱胺前体化合物
JP7778685B2 (ja) *	2020-04-30	2025-12-02	富士フイルム富山化学株式会社	ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤
US20230210816A1 (en) *	2020-05-27	2023-07-06	University Of Washington	Inhibition of arenaviruses by combinations of approved therapeutic drugs
IL315480A (en)	2022-03-15	2024-11-01	Rome Therapeutics Inc	Compounds and methods for treating disease
CN116813985B (zh) *	2023-07-14	2024-02-09	唐山学院	一种用于硫化氢气体的预警材料及其制备方法

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4107288A (en)	1974-09-18	1978-08-15	Pharmaceutical Society Of Victoria	Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4353656A (en)	1980-10-14	1982-10-12	Xerox Corporation	Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de)	1981-07-08	1986-12-11	Draco Ab	Powder inhalator
GB2129691B (en)	1982-10-08	1987-08-05	Glaxo Group Ltd	Devices for administering medicaments to patients
US4778054A (en)	1982-10-08	1988-10-18	Glaxo Group Limited	Pack for administering medicaments to patients
AU591152B2 (en)	1985-07-30	1989-11-30	Glaxo Group Limited	Devices for administering medicaments to patients
GB9004781D0 (en)	1990-03-02	1990-04-25	Glaxo Group Ltd	Device
AP249A (en)	1990-04-24	1993-03-17	Biota Scient Management Pty Ltd	Anti-viral compounds.
GB9021433D0 (en)	1990-10-02	1990-11-14	Atomic Energy Authority Uk	Power inhaler
US5145684A (en)	1991-01-25	1992-09-08	Sterling Drug Inc.	Surface modified drug nanoparticles
GB9126725D0 (en)	1991-12-17	1992-02-12	Glaxo Group Ltd	Process
GB9127376D0 (en)	1991-12-24	1992-02-19	Wellcome Found	Amidino derivatives
US5552438A (en)	1992-04-02	1996-09-03	Smithkline Beecham Corporation	Compounds useful for treating allergic and inflammatory diseases
US6156544A (en)	1993-06-09	2000-12-05	Glaxo Group Limited	Process for the preparation of N-acetylneuraminic acid
GB9312531D0 (en)	1993-06-17	1993-08-04	Glaxo Group Ltd	Process
DE59410119D1 (de)	1993-07-02	2002-06-20	Byk Gulden Lomberg Chem Fab	Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren
DE69529101T2 (de)	1994-06-15	2003-11-13	Wellcome Found	Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren
US5866601A (en)	1995-02-27	1999-02-02	Gilead Sciences, Inc.	Carbocyclic compounds
CN100409844C (zh)	1995-02-27	2008-08-13	吉里德科学公司	神经氨酸苷酶抑制剂
EP0813490B1 (en)	1995-03-10	2000-07-12	Minnesota Mining And Manufacturing Company	Aerosol valves
US5622166A (en)	1995-04-24	1997-04-22	Dura Pharmaceuticals, Inc.	Dry powder inhaler delivery system
US5763483A (en)	1995-12-29	1998-06-09	Gilead Sciences, Inc.	Carbocyclic compounds
GB9700226D0 (en)	1997-01-08	1997-02-26	Glaxo Group Ltd	Inhalation device
MY117948A (en)	1997-01-13	2004-08-30	Glaxo Group Ltd	Nitride oxide synthase inhibitors.
DE19723722A1 (de)	1997-05-30	1998-12-10	Schering Ag	Nichtsteroidale Gestagene
WO1999016766A1 (en)	1997-10-01	1999-04-08	Kyowa Hakko Kogyo Co., Ltd.	Benzodioxole derivatives
US6506766B1 (en)	1998-02-13	2003-01-14	Abbott Laboratories	Glucocortiocoid-selective antinflammatory agents
SI1070056T1 (en)	1998-03-14	2004-12-31	Altana Pharma Ag	Phthalazinone pde iii/iv inhibitors
GB9811599D0 (en)	1998-05-30	1998-07-29	Glaxo Group Ltd	Nitric oxide synthase inhibitors
WO2000066590A2 (en)	1999-05-04	2000-11-09	Ligand Pharmaceuticals, Inc.	Tetracyclic progesterone receptor modulator compounds and methods
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CO5180649A1 (es)	1999-09-01	2002-07-30	Abbott Lab	Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
OA11558A (en)	1999-12-08	2004-06-03	Advanced Medicine Inc	Beta 2-adrenergic receptor agonists.
US6632666B2 (en)	2000-01-14	2003-10-14	Biolife Solutions, Inc.	Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
JP2004504270A (ja)	2000-03-10	2004-02-12	スミスクライン・ビーチャム・コーポレイション	Ｉｌ−８受容体アンタゴニスト
EP1307190A4 (en) *	2000-07-18	2007-08-22	Smithkline Beecham Corp	USE OF IL-8 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VIRUS INFECTIONS
SI1775305T1 (sl)	2000-08-05	2015-01-30	Glaxo Group Limited	S-fluorometil ester 6alfa,9alfa-difluoro-17alfa-((2-furanilkarboksil)oksi)- 11beta-hidroksi-16alfa-metil-3-okso-androst-1,4-dien-17-karbotiojske kisline kot protivnetno sredstvo
EP1324990B1 (en)	2000-09-29	2014-10-29	Glaxo Group Limited	Morpholin-acetamide derivatives for the treatment of inflammatory diseases
GB0031179D0 (en)	2000-12-21	2001-01-31	Glaxo Group Ltd	Nitric oxide synthase inhibitors
GB0103630D0 (en)	2001-02-14	2001-03-28	Glaxo Group Ltd	Chemical compounds
US7144908B2 (en)	2001-03-08	2006-12-05	Glaxo Group Limited	Agonists of beta-adrenoceptors
ES2296923T3 (es)	2001-03-22	2008-05-01	Glaxo Group Limited	Derivados formanilidas como agonistas del adrenorreceptor beta2.
KR100831534B1 (ko)	2001-04-30	2008-05-22	글락소 그룹 리미티드	17.알파 위치에 시클릭 에스테르기를 지닌 항염증성의안드로스탄의 17.베타.-카르보티오에이트 에스테르 유도체
ES2307751T3 (es)	2001-06-12	2008-12-01	Glaxo Group Limited	Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
KR20090057477A (ko)	2001-09-14	2009-06-05	글락소 그룹 리미티드	호흡기 질환 치료용 펜에탄올아민 유도체
US6653323B2 (en)	2001-11-13	2003-11-25	Theravance, Inc.	Aryl aniline β2 adrenergic receptor agonists
AU2003202216A1 (en)	2002-01-14	2003-07-30	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
CA2473886C (en)	2002-01-22	2012-08-21	The Regents Of The University Of California	Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
GB0204719D0 (en)	2002-02-28	2002-04-17	Glaxo Group Ltd	Medicinal compounds
CA2478156C (en)	2002-03-26	2011-02-15	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2003082787A1 (en)	2002-03-26	2003-10-09	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de)	2002-04-02	2003-12-18	Schering Ag	Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
EP1496892B1 (en)	2002-04-11	2011-01-26	Merck Sharp & Dohme Corp.	1h-benzo(f)indazol-5-yl derivatives as selective glucocorticoid receptor modulators
JP2005523920A (ja)	2002-04-25	2005-08-11	グラクソ　グループ　リミテッド	フェネタノールアミン誘導体
US7186864B2 (en)	2002-05-29	2007-03-06	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en)	2002-06-06	2006-07-11	Boehringer Ingelheim Pharmaceuticals, Inc.	Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP4503436B2 (ja)	2002-07-08	2010-07-14	ファイザー・プロダクツ・インク	糖質コルチコイド受容体のモジュレーター
EP1534273A4 (en)	2002-07-18	2007-08-22	Bristol Myers Squibb Co	MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
GB0217225D0 (en)	2002-07-25	2002-09-04	Glaxo Group Ltd	Medicinal compounds
JP2006504678A (ja)	2002-08-21	2006-02-09	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	グルココルチコイドミメチックス、その製造方法、その医薬組成物、及び使用
GB0220730D0 (en)	2002-09-06	2002-10-16	Glaxo Group Ltd	Medicinal compounds
GB0230045D0 (en)	2002-12-23	2003-01-29	Glaxo Group Ltd	Compounds
JP2006503108A (ja)	2002-09-16	2006-01-26	グラクソ　グループ　リミテッド	ピラゾロ［３，４−ｂ］ピリジン化合物およびそれのホスホジエステラーゼ阻害薬としての使用
AU2003270783C1 (en)	2002-09-20	2010-05-20	Merck Sharp & Dohme Corp.	Octahydro-2-H-naphtho[1,2-F] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
GB0224084D0 (en)	2002-10-16	2002-11-27	Glaxo Group Ltd	Novel compounds
EP1554264B1 (en)	2002-10-22	2007-08-08	Glaxo Group Limited	Medicinal arylethanolamine compounds
GB0225030D0 (en)	2002-10-28	2002-12-04	Glaxo Group Ltd	Medicinal compounds
EP1556342B1 (en)	2002-10-28	2008-03-26	Glaxo Group Limited	Phenethanolamine derivative for the treatment of respiratory diseases
GB0225535D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
GB0225540D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Medicinal compounds
US20060293298A1 (en)	2003-04-10	2006-12-28	Bamford Mark J	Compounds
TWI328009B (en)	2003-05-21	2010-08-01	Glaxo Group Ltd	Quinoline derivatives as phosphodiesterase inhibitors
GB0316290D0 (en)	2003-07-11	2003-08-13	Glaxo Group Ltd	Novel compounds
WO2005037280A1 (en)	2003-10-14	2005-04-28	Glaxo Group Limited	Muscarinic acetycholine receptor antagonists
PE20050489A1 (es)	2003-11-04	2005-09-02	Glaxo Group Ltd	Antagonistas de receptores de acetilcolina muscarinicos
AU2004299277A1 (en)	2003-12-19	2005-06-30	Glaxo Group Limited	Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
US20080275078A1 (en)	2004-03-16	2008-11-06	Glaxo Group Limited	Pyrazolo[3,4-B] Pyridine Compounds and Their Use as Pde4 Inhibitors
GB0405933D0 (en)	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
GB0405937D0 (en)	2004-03-16	2004-04-21	Glaxo Group Ltd	Compounds
UY28871A1 (es)	2004-04-27	2005-11-30	Glaxo Group Ltd	Antagonistas del receptor de acetilcolina muscarinico
WO2006000401A1 (en)	2004-06-28	2006-01-05	Glaxo Group Limited	Substituted oxazines as glucocorticoid receptor modulators
WO2006000398A1 (en)	2004-06-28	2006-01-05	Glaxo Group Limited	2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators
GB0418045D0 (en)	2004-08-12	2004-09-15	Glaxo Group Ltd	Compounds
MX2007004465A (es)	2004-10-19	2007-05-07	Hoffmann La Roche	Derivados de quinolina.
EP1841780B1 (en)	2005-01-10	2011-07-27	Glaxo Group Limited	Androstane 17-alpha-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
US20090124588A1 (en)	2005-01-10	2009-05-14	Glaxo Group Limited	Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
WO2006090142A1 (en)	2005-02-24	2006-08-31	Glaxo Group Limited	l-{4- [ (l-CYCLOBUTYL-4-PIPERIDINYL) OXY] PHENYL] -4-{ [4- (METHYLSULFONYL) PHENYL]CARBONYL PIPERAZINE AS HISTAMINE H3 ANTAGONIST
JP2008535884A (ja)	2005-04-14	2008-09-04	グラクソグループリミテッド	グルココルチコイド受容体リガンドとしてのインダゾール
GB0513297D0 (en)	2005-06-29	2005-08-03	Glaxo Group Ltd	Novel compounds
GB0514811D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
GB0514812D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
GB0522880D0 (en)	2005-11-09	2005-12-21	Glaxo Group Ltd	Novel compounds
PE20071068A1 (es)	2005-12-20	2007-12-13	Glaxo Group Ltd	Acido 3-(4-{[4-(4-{[3-(3,3-dimetil-1-piperidinil)propil]oxi}fenil)-1-piperidinil]carbonil}-1-naftalenil)propanoico o propenoico, sales de los mismos, como antagonistas de los receptores h1 y h3
MX2008013411A (es)	2006-04-20	2008-11-04	Glaxo Group Ltd	Nuevos compuestos.
US20080039444A1 (en)	2006-04-20	2008-02-14	Glaxo Group Limited	Compounds
PL2009992T3 (pl) *	2006-04-21	2012-11-30	Glaxosmithkline Llc	Antagoniści receptora IL-8
GB0609897D0 (en)	2006-05-18	2006-06-28	Glaxo Group Ltd	Compounds
GB0611587D0 (en)	2006-06-12	2006-07-19	Glaxo Group Ltd	Novel compounds
WO2008000777A2 (en)	2006-06-29	2008-01-03	Glaxo Group Limited	Phenyl- pyrazole derivatives, process for their preparation and their pharmaceutical use
GB201320021D0 (en) *	2013-11-13	2013-12-25	Glaxosmithkline Ip Dev Ltd	Novel Compounds

2015
- 2015-05-08 US US15/310,592 patent/US20170100385A1/en not_active Abandoned
- 2015-05-08 CN CN201580038007.5A patent/CN107072976A/zh active Pending
- 2015-05-08 PE PE2016002229A patent/PE20170185A1/es not_active Application Discontinuation
- 2015-05-08 SG SG11201609276RA patent/SG11201609276RA/en unknown
- 2015-05-08 JP JP2016567399A patent/JP2017515840A/ja active Pending
- 2015-05-08 AU AU2015260841A patent/AU2015260841A1/en not_active Abandoned
- 2015-05-08 CR CR20160529A patent/CR20160529A/es unknown
- 2015-05-08 CA CA2948441A patent/CA2948441A1/en not_active Abandoned
- 2015-05-08 KR KR1020167034634A patent/KR20170003673A/ko not_active Withdrawn
- 2015-05-08 UY UY0001036117A patent/UY36117A/es not_active Application Discontinuation
- 2015-05-08 WO PCT/IB2015/053373 patent/WO2015173701A2/en not_active Ceased
- 2015-05-08 MX MX2016014859A patent/MX2016014859A/es unknown
- 2015-05-08 EP EP15721878.5A patent/EP3142694A2/en not_active Withdrawn
- 2015-05-08 TW TW104114803A patent/TW201625247A/zh unknown
- 2015-05-08 EA EA201692111A patent/EA201692111A1/ru unknown
2016
- 2016-11-06 IL IL248779A patent/IL248779A0/en unknown
- 2016-11-09 ZA ZA2016/07729A patent/ZA201607729B/en unknown
- 2016-11-11 PH PH12016502243A patent/PH12016502243A1/en unknown
- 2016-11-11 DO DO2016000297A patent/DOP2016000297A/es unknown
- 2016-11-11 CL CL2016002879A patent/CL2016002879A1/es unknown
2018
- 2018-03-19 US US15/924,952 patent/US20180207145A1/en not_active Abandoned
- 2018-06-04 AU AU2018203911A patent/AU2018203911A1/en not_active Abandoned

Publication	Publication Date	Title
JP2017515840A5 (2)	2018-05-31
JP2009535352A5 (2)	2010-06-03
JP2015534562A5 (2)	2016-11-24
CY1119490T1 (el)	2018-03-07	Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
JP2010285436A5 (2)	2012-07-26
JP2012255026A5 (2)	2013-02-21
MX2012007410A (es)	2012-07-17	Compuestos antivirales novedosos.
JP2013542247A5 (2)	2014-12-18
JP2020097577A5 (2)	2020-10-08
JP2013519675A5 (2)	2014-03-27
JP2014167010A5 (2)	2014-12-18
JP2013518107A5 (2)	2014-03-13
JP2016528301A5 (2)	2017-09-28
SI2709613T1 (en)	2018-01-31	Procedures for the treatment of HCV
HRP20240168T1 (hr)	2024-04-26	Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije
ME02400B (me)	2016-09-20	Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
JP2010270130A5 (2)	2012-07-26
JP2018513188A5 (2)	2019-05-30
JP2017517565A5 (2)	2018-06-21
JP2015516419A5 (2)	2016-06-16
JP2009544665A5 (2)	2010-08-26
JP2015516975A5 (2)	2016-05-19
JP2015518007A5 (2)	2016-06-30
RU2014112324A (ru)	2015-10-10	Применение органического соединения для лечения синдрома нунан
JP2016540000A5 (2)	2018-02-01